replication defective Tat-expressing HSV-1 vector vaccine (HSV 1 & 2 infection) (Vaxxit)

N/A

Report date: 2025/01/26 16:51:41

Base Information

Drug Namereplication defective Tat-expressing HSV-1 vector vaccine (HSV 1 & 2 infection) (Vaxxit)
Drug Alias NameHerpesVaxTat
ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine +[4] 
Mechanisms of ActionHuman Immunodeficiency Virus tat Gene Products modulators
TargetsHuman Immunodeficiency Virus tat Gene Products
Therapy Area/IndicationsHerpes Simplex Virus Type 2 InfectionsHerpes Simplex Virus Type 1 Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVaxxit
China Registration ClassN/A

Develop Information

Active CompaniesVaxxit
Inactive CompaniesN/A
Active IndicationsHerpes Simplex Virus Type 2 InfectionsHerpes Simplex Virus Type 1 Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A